Related Experiment Video
Updated: May 28, 2026
05:58
Site-Specific Lysine Lactylation via Genetic Code Expansion in E. coli and Mammalian Cells
Published on: February 24, 2026
Lactylation in Colorectal Cancer: Regulatory Networks, Functional Mechanisms, and Clinical Translational Potential
Diao Wei1,2,3, Min Zhang1,2,3, Tianyu Lei2,3
1Department of Oncology, Renmin Hospital of Wuhan University, No. 99 Zhangzhidong Road, Wuchang District, Wuhan 430060, China.
International Journal of Molecular Sciences
|May 27, 2026
Summary
Protein lactylation, a key metabolic regulator in colorectal cancer (CRC), drives tumor progression and therapy resistance. Understanding lactylation
Area of Science:
- Oncology
- Metabolic Regulation
- Epigenetics
Background:
- Protein lactylation, a post-translational modification driven by lactate, is crucial in colorectal cancer (CRC).
- The CRC microenvironment, influenced by the Warburg effect and microbial metabolism, provides substrates for lactylation.
- Lactylation interacts with other modifications like acetylation and ubiquitination, impacting cellular functions.
Purpose of the Study:
- To systematically review the regulatory networks and biological functions of lactylation in CRC.
- To elucidate mechanisms of therapy resistance conferred by lactylation.
- To discuss the clinical potential of lactylation as a biomarker and therapeutic target.
Main Methods:
- Literature review and synthesis of existing research on protein lactylation in CRC.
- Analysis of regulatory enzymes (Writers and Erasers) involved in lactylation.
- Examination of lactylation's functional roles in tumor progression and treatment resistance.
Main Results:
- Lactylation drives CRC proliferation, invasion, metastasis, and remodels the tumor microenvironment.
- It confers resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy.
- Lactylation enhances DNA damage repair and activates autophagy, contributing to ferroptosis defense.
Conclusions:
- Lactylation is a critical factor in CRC pathogenesis and therapeutic resistance.
- Targeting lactylation pathways offers potential for novel diagnostic and therapeutic strategies in CRC.
- Further research is needed to translate these findings into clinical applications for CRC treatment.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...